Futibatinib plus Fulvestrant for Breast Cancer
This trial is testing a drug to see if it works better than current treatments for metastatic breast cancer in patients with a specific gene abnormality. They will also be testing to see if the drug has any serious side effects.
- Metastatic Breast Cancer
- Fibroblast Growth Factor Receptor 1 High Amplification
- No disease or condition mentioned.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What have been the side effects of Futibatinib in combination with Fulvestrant?
"Futibatinib plus Fulvestrant is still being studied in clinical trials, so its safety rating is a 2."
What are Futibatinib and Fulvestrant most frequently used to treat?
"Futibatinib in combination with Fulvestrant has been shown to be effective at treating patients that have received prior endocrine therapy, disease, or breast cancer."
Are Futibatinib and Fulvestrant commonly used together in research?
"Currently, there are 147 clinical trials studying Futibatinib plus Fulvestrant. 35 of those active clinical trials are in Phase 3. While the majority of trials for Futibatinib plus Fulvestrant are based in Shanghai, China, there are 6064 locations running studies for this treatment worldwide."
Are we still enrolling people in this experiment?
"Yes. The trial, which began recruitment on 8/30/2019 and was most recently updated on 10/4/2022, is still recruiting participants. There are 168 total spots at 11 different sites around the country."
Are there several hospitals running this study in the city?
"Enrolment for this clinical trial is happening at 11 sites. They are situated in San Francisco, Toronto, Houston as well as 8 other locations. If you enrol in the study, try to pick a site close to your residence to limit travel time and expenses."
How many individuals are involved in this research project?
"168 patients that meet the clinical trial's inclusion criteria are required in order for the study to run as planned. The sponsor, Taiho Oncology, Inc., has different medical centres across North America where the trial will take place; two examples include USCF in San Francisco and SunnyBrook Health Sciences in Toronto."